|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/29/18 Acasti Pharma Inc. 20-F 3/31/18 110:35M Globenewswire Inc./FA |
Document/Exhibit Description Pages Size
1: 20-F Annual Report by a Foreign Non-Canadian Issuer HTML 1.24M
2: EX-2.4 Plan of Acquisition, Reorganization, Arrangement, HTML 44K
Liquidation or Succession
3: EX-2.5 Plan of Acquisition, Reorganization, Arrangement, HTML 58K
Liquidation or Succession
6: EX-13.1 Annual or Quarterly Report to Security Holders HTML 31K
7: EX-13.2 Annual or Quarterly Report to Security Holders HTML 31K
4: EX-12.1 Statement re: Computation of Ratios HTML 35K
5: EX-12.2 Statement re: Computation of Ratios HTML 36K
8: EX-15.1 Letter re: Unaudited Interim Financial Info HTML 34K
15: R1 Document And Entity Information HTML 57K
16: R2 Statements of Financial Position (February 2017 HTML 93K
Unaudited)
17: R3 Statements of Earnings and Comprehensive Loss HTML 60K
(Twelve Month and Month Ended 2017 Unaudited)
18: R4 Statements of Changes in Equity (Twelve Month and HTML 108K
Month Ended 2017 Unaudited)
19: R5 Statements of Changes in Equity (Twelve Month and HTML 34K
Month Ended 2017 Unaudited) (Parentheticals)
20: R6 Statements of Cash Flows (Twelve Month and Month HTML 111K
Ended 2017 Unaudited)
21: R7 Note 1 - Reporting Entity HTML 39K
22: R8 Note 2 - Basis of Preparation HTML 52K
23: R9 Note 3 - Significant Accounting Policies HTML 95K
24: R10 Note 4 - Receivables HTML 43K
25: R11 Note 5 - Other Assets HTML 34K
26: R12 Note 6 - Related Parties HTML 84K
27: R13 Note 7 - Government Assistance HTML 53K
28: R14 Note 8 - Equipment HTML 90K
29: R15 Note 9 - Intangible Assets HTML 65K
30: R16 Note 10 - Trade and Other Payables HTML 44K
31: R17 Note 11 - Derivative Warrant Liabilities HTML 88K
32: R18 Note 12 - Unsecured Convertible Debentures HTML 64K
33: R19 Note 13 - Capital and Other Components of Equity HTML 140K
34: R20 Note 14 - Personnel Expenses HTML 47K
35: R21 Note 15 - Financial Expenses HTML 69K
36: R22 Note 16 - Share-based Payments HTML 120K
37: R23 Note 17 - Loss Per Share HTML 33K
38: R24 Note 18 - Supplemental Cash Flow Disclosure HTML 75K
39: R25 Note 19 - Income Taxes HTML 107K
40: R26 Note 20 - Financial Instruments HTML 124K
41: R27 Note 21 - Commitments and Contingencies HTML 39K
42: R28 Note 22 - Determination of Fair Values HTML 39K
43: R29 Note 23 - Capital Management HTML 49K
44: R30 Note 24 - Subsequent Event HTML 39K
45: R31 Significant Accounting Policies (Policies) HTML 132K
46: R32 Note 3 - Significant Accounting Policies (Tables) HTML 38K
47: R33 Note 4 - Receivables (Tables) HTML 42K
48: R34 Note 6 - Related Parties (Tables) HTML 75K
49: R35 Note 7 - Government Assistance (Tables) HTML 53K
50: R36 Note 8 - Equipment (Tables) HTML 88K
51: R37 Note 9 - Intangible Assets (Tables) HTML 63K
52: R38 Note 10 - Trade and Other Payables (Tables) HTML 43K
53: R39 Note 11 - Derivative Warrant Liabilities (Tables) HTML 87K
54: R40 Note 12 - Unsecured Convertible Debentures HTML 57K
(Tables)
55: R41 Note 13 - Capital and Other Components of Equity HTML 114K
(Tables)
56: R42 Note 14 - Personnel Expenses (Tables) HTML 47K
57: R43 Note 15 - Financial Expenses (Tables) HTML 68K
58: R44 Note 16 - Share-based Payments (Tables) HTML 107K
59: R45 Note 18 - Supplemental Cash Flow Disclosure HTML 75K
(Tables)
60: R46 Note 19 - Income Taxes (Tables) HTML 108K
61: R47 Note 20 - Financial Instruments (Tables) HTML 119K
62: R48 Note 23 - Capital Management (Tables) HTML 40K
63: R49 Note 1 - Reporting Entity (Details Textual) HTML 36K
64: R50 Note 2 - Basis of Preparation (Details Textual) HTML 46K
65: R51 Note 3 - Significant Accounting Policies (Details HTML 37K
Textual)
66: R52 Note 3 - Significant Accounting Policies - HTML 50K
Estimated Useful Lives and Rates (Details)
67: R53 Note 4 - Receivables - Schedule of Receivables HTML 40K
(Details)
68: R54 Note 5 - Other Assets (Details Textual) HTML 44K
69: R55 Note 6 - Related Parties (Details Textual) HTML 58K
70: R56 Note 6 - Related Parties - Administrative and HTML 47K
Research and Development Expenses (Details)
71: R57 Note 6 - Related Parties - Key Management HTML 41K
Personnel Compensation (Details)
72: R58 Note 7 - Government Assistance - Government Grants HTML 37K
and Investment Tax Credits (Details)
73: R59 Note 7 - Government Assistance - Unrecognized HTML 54K
Federal Tax Credits (Details)
74: R60 Note 8 - Equipment (Details Textual) HTML 34K
75: R61 Note 8 - Equipment - Components of Equipment HTML 77K
(Details)
76: R62 Note 9 - Intangible Assets - Components of HTML 66K
Intangible Assets (Details)
77: R63 Note 10 - Trade and Other Payables - Components of HTML 43K
Trade and Other Payables (Details)
78: R64 Note 11 - Derivative Warrant Liabilities (Details HTML 39K
Textual)
79: R65 Note 11 - Derivative Warrant Liabilities - HTML 46K
Reconciliation (Details)
80: R66 Note 11 - Derivative Warrant Liabilities - HTML 53K
Assumptions (Details)
81: R67 Note 12 - Unsecured Convertible Debentures HTML 56K
(Details Textual)
82: R68 Note 12 - Unsecured Convertible Debentures - HTML 56K
Liability and Equity Component Portions (Details)
83: R69 Note 13 - Capital and Other Components of Equity HTML 198K
(Details Textual)
84: R70 Note 13 - Capital and Other Components of Equity - HTML 47K
Assumptions (Details)
85: R71 Note 13 - Capital and Other Components of Equity - HTML 36K
Unsecured Convertible Debentures (Details)
86: R72 Note 13 - Capital and Other Components of Equity - HTML 67K
Warrants Outstanding (Details)
87: R73 Note 14 - Personnel Expenses - Components of HTML 42K
Personnel Expenses (Details)
88: R74 Note 15 - Financial Expenses - Components of HTML 60K
Finance Income (Expenses) (Details)
89: R75 Note 16 - Share-based Payments (Details Textual) HTML 74K
90: R76 Note 16 - Share-based Payments - Option Activity HTML 63K
(Details)
91: R77 Note 16 - Share-based Payments - Weighted Average HTML 46K
Assumptions (Details)
92: R78 Note 16 - Share-based Payments - Outstanding and HTML 81K
Exercisable Options (Details)
93: R79 Note 18 - Supplemental Cash Flow Disclosure - HTML 48K
Changes in Non-cash Operating Items (Details)
94: R80 Note 18 - Supplemental Cash Flow Disclosure - HTML 50K
Non-cash Transactions (Details)
95: R81 Note 19 - Income Taxes (Details Textual) HTML 33K
96: R82 Note 19 - Income Taxes - Deferred Tax (Recovery) HTML 42K
Expense (Details)
97: R83 Note 19 - Income Taxes - Reconciliation of HTML 56K
Effective Tax Rate (Details)
98: R84 Note 19 - Income Taxes - Unrecognized Deferred Tax HTML 52K
Assets (Details)
99: R85 Note 19 - Income Taxes - Tax attributes and HTML 72K
Temporary Differences Available to Reduce Future
Years' Taxable Income (Details)
100: R86 Note 20 - Financial Instruments - Currency Risk HTML 61K
(Details)
101: R87 Note 20 - Financial Instruments - Interest Rate HTML 37K
Risk (Details)
102: R88 Note 20 - Financial Instruments - Financial HTML 54K
Liabilities (Details)
103: R89 Note 21 - Commitments and Contingencies (Details HTML 48K
Textual)
104: R90 Note 22 - Determination of Fair Values (Details HTML 36K
Textual)
105: R91 Note 23 - Capital Management (Details Textual) HTML 60K
106: R92 Note 23 - Capital Management - Cash and Cash HTML 38K
Equivalents (Details)
107: R93 Note 24 - Subsequent Event (Details Textual) HTML 77K
109: XML IDEA XML File -- Filing Summary XML 199K
108: EXCEL IDEA Workbook of Financial Reports XLSX 110K
9: EX-101.INS XBRL Instance -- acst-20180331 XML 3.75M
11: EX-101.CAL XBRL Calculations -- acst-20180331_cal XML 155K
12: EX-101.DEF XBRL Definitions -- acst-20180331_def XML 1.53M
13: EX-101.LAB XBRL Labels -- acst-20180331_lab XML 1.19M
14: EX-101.PRE XBRL Presentations -- acst-20180331_pre XML 1.55M
10: EX-101.SCH XBRL Schema -- acst-20180331 XSD 322K
110: ZIP XBRL Zipped Folder -- 0001171843-18-004911-xbrl Zip 227K
Exhibit 12.2
SECTION 302 CERTIFICATION
I, Linda P. O’Keefe, certify that:
| 1. | I have reviewed this annual report on Form 20-F of Acasti Pharma Inc.; | |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d–15(f)) for the company and have: | |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| d) | Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and | |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions): | |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and | |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting. | |
| /s/ Linda P. O’Keefe |
Name: Linda P. O’Keefe
Title: Principal Financial Officer
| This ‘20-F’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 6/29/18 | |||
| For Period end: | 3/31/18 | 6-K | ||
| List all Filings | ||||